Literature DB >> 26977279

The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.

James Crane1, Barbara McGowan2.   

Abstract

There is a global obesity epidemic that will continue to be a financial burden on healthcare systems around the world. Tackling obesity through diet and exercise should always be the first intervention, but this has not proved to be effective for a large number of patients. Pharmacotherapeutic options have been limited and many previously available drugs have been withdrawn due to safety concerns. Currently, only bariatric surgery has the capability to induce both substantial and durable weight loss. This article briefly reviews the history of pharmacotherapy for obesity before focusing on the clinical trial evidence for the use of the GLP-1 agonist liraglutide as a weight loss agent and comparing its efficacy with other emerging drug therapies for obesity.

Entities:  

Keywords:  liraglutide; obesity; pharmacotherapy

Year:  2015        PMID： 26977279      PMCID： PMC4772342          DOI： 10.1177/2040622315620180

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


  84 in total

1.  Obesity and osteoarthritis of the knee: evidence from the National Health and Nutrition Examination Survey (NHANES I).

Authors:  M A Davis; W H Ettinger; J M Neuhaus
Journal:  Semin Arthritis Rheum       Date:  1990-12       Impact factor: 5.532

2.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

3.  Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Authors:  M Weintraub; P R Sundaresan; M Madan; B Schuster; A Balder; L Lasagna; C Cox
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

4.  Body-mass index and mortality among 1.46 million white adults.

Authors:  Amy Berrington de Gonzalez; Patricia Hartge; James R Cerhan; Alan J Flint; Lindsay Hannan; Robert J MacInnis; Steven C Moore; Geoffrey S Tobias; Hoda Anton-Culver; Laura Beane Freeman; W Lawrence Beeson; Sandra L Clipp; Dallas R English; Aaron R Folsom; D Michal Freedman; Graham Giles; Niclas Hakansson; Katherine D Henderson; Judith Hoffman-Bolton; Jane A Hoppin; Karen L Koenig; I-Min Lee; Martha S Linet; Yikyung Park; Gaia Pocobelli; Arthur Schatzkin; Howard D Sesso; Elisabete Weiderpass; Bradley J Willcox; Alicja Wolk; Anne Zeleniuch-Jacquotte; Walter C Willett; Michael J Thun
Journal:  N Engl J Med       Date:  2010-12-02       Impact factor: 91.245

5.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Rational design of a combination medication for the treatment of obesity.

Authors:  Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2008-11-06       Impact factor: 5.002

7.  Hamster preproglucagon contains the sequence of glucagon and two related peptides.

Authors:  G I Bell; R F Santerre; G T Mullenbach
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

Review 8.  Long-term pharmacotherapy for obesity and overweight.

Authors:  R Padwal; S K Li; D C W Lau
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 9.  The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.

Authors:  J Picot; J Jones; J L Colquitt; E Gospodarevskaya; E Loveman; L Baxter; A J Clegg
Journal:  Health Technol Assess       Date:  2009-09       Impact factor: 4.014

10.  The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England.

Authors:  F Søltoft; M Hammer; N Kragh
Journal:  Qual Life Res       Date:  2009-10-08       Impact factor: 4.147
View more
  10 in total

1.  Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components.

Authors:  G J Ooi; L Doyle; T Tie; J M Wentworth; C Laurie; A Earnest; M A Cowley; K Sikaris; C W le Roux; P R Burton; P E O'Brien; W A Brown
Journal:  Int J Obes (Lond)       Date:  2017-03-06       Impact factor: 5.095

2.  Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.

Authors:  Shuang Song; Ruoyi Guo; Arshad Mehmood; Lu Zhang; Bowen Yin; Congcong Yuan; Huining Zhang; Li Guo; Bin Li
Journal:  CNS Neurosci Ther       Date:  2022-01-05       Impact factor: 5.243

Review 3.  Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.

Authors:  Hyunmi Kim; Da Som Lee; Tae Hyeon An; Hyun-Ju Park; Won Kon Kim; Kwang-Hee Bae; Kyoung-Jin Oh
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 4.  Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.

Authors:  Filipe Ferrari; Rafael S Scheffel; Vítor M Martins; Raul D Santos; Ricardo Stein
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-27       Impact factor: 3.283

5.  Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center.

Authors:  Daniela Sofra
Journal:  Diabetes Ther       Date:  2017-02-20       Impact factor: 2.945

6.  Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability.

Authors:  Ruba Ismail; Alexandra Bocsik; Gábor Katona; Ilona Gróf; Mária A Deli; Ildikó Csóka
Journal:  Pharmaceutics       Date:  2019-11-12       Impact factor: 6.321

Review 7.  Clinical Impact of Liraglutide as a Treatment of Obesity.

Authors:  Heshma Alruwaili; Babak Dehestani; Carel W le Roux
Journal:  Clin Pharmacol       Date:  2021-03-11

8.  The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.

Authors:  Anna Thorsø Larsen; Sofie Gydesen; Nina Sonne; Morten Asser Karsdal; Kim Henriksen
Journal:  BMC Endocr Disord       Date:  2021-01-07       Impact factor: 2.763

Review 9.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

10.  The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity.

Authors:  Yuko Maejima; Shoko Yokota; Masaru Shimizu; Shoichiro Horita; Daisuke Kobayashi; Akihiro Hazama; Kenju Shimomura
Journal:  Nutr Metab (Lond)       Date:  2021-06-07       Impact factor: 4.169
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.